AstraZeneca’s oral relaxin agonist posted a mid-stage readout suggesting potential benefit in a heart-failure population, but not uniformly across all groups. Presented at ESC and reported from Munich, the Phase 2 trial data indicate improved cardiac function in some patients while leaving room for refinement in later studies. The result is notable because it targets a new mechanism in heart failure drug development, aiming to affect cardiac performance through relaxin receptor signaling rather than established neurohormonal or metabolic pathways. For AstraZeneca, the partial efficacy profile determines the design priorities for future confirmatory trials—especially around patient selection and dosing strategies—if the program is to progress as a competitive alternative in a crowded class landscape.